The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
- Dysphagia+(swallowing)
- 125
Filter Results (2440)
- Mitochondrial Biomarkers Program, 2018Studying the Production of Mitochondria to Find New Therapeutic Targets for Parkinson's Disease
Study Rationale:
It is known that the brain cells damaged in Parkinson's disease (PD) struggle to generate energy. This is because mitochondria -- powerhouses of the cell -- are faulty in these cells... - Therapeutic Pipeline Program, 2018Disease-modifying Glucocerebrosidase Therapy for Parkinson's Disease
Study Rationale:
Many people with Parkinson's disease (PD) have an abnormal glucocerebrosidase (GBA) enzyme, which causes them to accumulate fatty acids -- chemicals that make up fat -- in the brain... - Mitochondrial Biomarkers Program, 2018N-formyl Peptides as Novel Biomarkers for Parkinson's Disease
Study Rationale:
Mitochondria -- the powerhouses of the cell -- have their own DNA that contains the instructions to make thirteen proteins. Fragments of these proteins, known as N-formyl peptides... - Target Advancement Program, 2018Searching for and Targeting Calcium Channels that Control Alpha-synuclein Release
Study Rationale:
Being the primary component of Lewy bodies -- protein clumps that are the pathological hallmark of Parkinson's disease (PD) -- the protein alpha-synuclein plays the central role in PD... - Research Grant, 2018PAK6 Activity as a Therapeutic Target in LRRK2-associated Parkinson's Disease
Study Rationale:
Mutations (changes) in the gene for the leucine-rich repeat kinase 2 (LRRK2) protein cause inherited Parkinson's disease (PD). Because the activity of LRRK2 is increased in such mutant... - Research Grant, 2018Studying Monocyte Entry into the Brain in Alpha-synuclein-induced Parkinson's Disease (supplement)
Study Rationale:
In the past, we demonstrated that entry of CCR2-positive monocytes into the brain is required for alpha-synuclein-induced inflammation and neurodegeneration in a model of Parkinson's...

Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.